Ignite Creation Date:
2025-12-25 @ 2:33 AM
Ignite Modification Date:
2026-03-01 @ 12:07 PM
Study NCT ID:
NCT06513234
Status:
RECRUITING
Last Update Posted:
2024-07-22
First Post:
2024-07-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-11
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-06-21
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-06-21
Completion Date Type:
ESTIMATED
First Submit Date:
2024-07-01
First Submit QC Date:
None
Study First Post Date:
2024-07-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-17
Last Update Post Date:
2024-07-22
Last Update Post Date Type:
ACTUAL